HomeCompareSOLTF vs NOBL

SOLTF vs NOBL: Dividend Comparison 2026

SOLTF yields 37.88% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SOLTF wins by $183.5K in total portfolio value
10 years
SOLTF
SOLTF
● Live price
37.88%
Share price
$5.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$206.4K
Annual income
$33,329.74
Full SOLTF calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SOLTF vs NOBL

📍 SOLTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSOLTFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SOLTF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SOLTF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SOLTF
Annual income on $10K today (after 15% tax)
$3,219.70/yr
After 10yr DRIP, annual income (after tax)
$28,330.28/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SOLTF beats the other by $28,117.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SOLTF + NOBL for your $10,000?

SOLTF: 50%NOBL: 50%
100% NOBL50/50100% SOLTF
Portfolio after 10yr
$114.7K
Annual income
$16,789.76/yr
Blended yield
14.64%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SOLTF buys
0
NOBL buys
0
No recent congressional trades found for SOLTF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSOLTFNOBL
Forward yield37.88%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$206.4K$22.9K
Annual income after 10y$33,329.74$249.78
Total dividends collected$152.8K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SOLTF vs NOBL ($10,000, DRIP)

YearSOLTF PortfolioSOLTF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$14,488$3,787.88$10,917$217.08+$3.6KSOLTF
2$20,631$5,128.82$11,903$221.48+$8.7KSOLTF
3$28,901$6,825.67$12,962$225.68+$15.9KSOLTF
4$39,860$8,936.20$14,099$229.68+$25.8KSOLTF
5$54,169$11,518.54$15,319$233.49+$38.9KSOLTF
6$72,590$14,629.36$16,628$237.10+$56.0KSOLTF
7$95,993$18,321.84$18,033$240.53+$78.0KSOLTF
8$125,356$22,643.78$19,539$243.78+$105.8KSOLTF
9$161,767$27,635.79$21,154$246.86+$140.6KSOLTF
10$206,420$33,329.74$22,884$249.78+$183.5KSOLTF

SOLTF vs NOBL: Complete Analysis 2026

SOLTFStock

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Full SOLTF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SOLTF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SOLTF vs SCHDSOLTF vs JEPISOLTF vs OSOLTF vs KOSOLTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.